Bryan Garnier - Delivery Hero (DHER) Delivery Hero: Talabat IPO to crystallise massive value and deleverage balance sheet

Report

Bryan Garnier

Clement Genelot

Delivery Hero: Talabat IPO to crystallise massive value and deleverage balance sheet

The recent CMD for Talabat ahead of the IPO demonstrated its superior profile with a prospective valuation of c.16x EV/EBITDA in our view, potentially raising c.EUR1.7bn for Delivery Hero and further deleveraging its balance sheet to such low levels that liquidity concerns would be permanently remo

10/10/2024 1 EN

Underlying

Delivery Hero

See profile

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Clement Genelot

Other Reports on these Companies

Bryan Garnier

On the shelves now: Consumer weekly #36

In this Consumer Weekly newsletter, we provide a brief overview of the key factors affecting our Consumer coverage, from Luxury & Consumer goods to Retail & E-commerce and Food & Ingredients. This week, we look at the US job market that is gradually cooling, prompting investors to bet o

July 8, 2024 July 8, 2024 1 EN

Bryan Garnier

On the shelves now: Consumer weekly #35

In this Consumer Weekly newsletter, we provide a brief overview of the key factors affecting our Consumer coverage, from Luxury & Consumer goods to Retail & E-commerce and Food & Ingredients. This week, we look at the political uncertainty that is clearly set to drive stock markets unti

July 1, 2024 July 1, 2024 1 EN

Avantium: PEF offtake contract from Plastipak

This morning Avantium announced it has signed a conditional offtake agreement with Plastipak, a world leader in the design and manufacture of high-quality, rigid plastic containers for the food, beverage and consumer products industries. Based on this new agreement, which follows the US FDA approva

17h / 28m 17h / 28m 1 EN

Oscar Haffen Lamm

Oscar Haffen Lamm

Vicore Pharma: interesting play in the IPF space

On the back of its SEK882m capital increase and the start of a phase 2b trial with its lead asset buloxibutid in IPF, we take the opportunity to refresh our investment case on Vicore Pharma. Going into the phase 2b, we appreciate the diverse multi-modal MoA that buloxibutid presents which are relev

October 9, 2024 October 9, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Delivery Hero: Talabat IPO to crystallise massive value and deleverage balance sheet

On the shelves now: Consumer weekly #36

On the shelves now: Consumer weekly #35

Avantium: PEF offtake contract from Plastipak

Vicore Pharma: interesting play in the IPF space

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe